Cardiac Safety

OVERVIEW

In vitro cardiac ion channel assays, including hERG, are a recognized and essential method of de-risking or eliminating potential cardiotoxicity issues in drug discovery. Our panel of patch-clamp and fluorescent human recombinant assays is configured to accurately assess the widest array of pharmacological and chemical entities, at a throughput and cost that enables these assays to be introduced early in your discovery program.

ESSEN CARDIAC PANEL

hERG	IKr delayed repolarisation	96-well Electrophysiology
hNaV1.5	INa upstroke	384-well Electrophysiology
hCaV1.2	ICa plateau	96-well Fluorescence
hKV1.5	Repolarisation	384-well Electrophysiology
hKCNQ1 +minK	IKS delayed repolarisation	Under construction

ASSAY CHARACTERISTICS

• Relevant and translational screening protocols, optimized for sensitivity and precision
• Rigorous quality control
• Comparable IC₅₀ values to conventional electrophysiology
• Low sample requirement - typically 2 mgs, or 100µL of 10mM stock
• High capacity - hundreds of samples at once if needed
• Fast turn-around - typically 1 week

Based on our intimate knowledge, expertise and capacity of the IonWorks and optical platforms, we offer quality, price points and turn-around times difficult to match by CRO’s who are simply end-user’s of our technology